Evidence map›Paper›PMID 30343086›Full record

ArticleJACC. Cardiovascular imaging2019

Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis.

Max L Senders, Sophie Hernot, Giuseppe Carlucci, Jan C van de Voort, Francois Fay, Claudia Calcagno, Jun Tang, Amr Alaarg, Yiming Zhao, Seigo Ishino and 18 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Cardiovascular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. PET imaging of atherosclerotic plaques using the stabilin-2-targeted tracerEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Immuno-positron emission tomography in cardiovascular disease: Advances, challenges, and opportunities.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2026
    Review
  4. Review
  5. From incidental positron emission uptake toFrontiers in cardiovascular medicine · 2026
    Review
  6. Review
  7. Radiolabeling lipoproteins to study and manage disease.European journal of nuclear medicine and molecular imaging · 2025
    Review
  8. Review
  9. Polymeric Nanomaterials for Atherosclerosis Diagnosis and Treatment.Polymer science & technology (Washington, D.C.) · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Nanomedicine for Diagnosis and Treatment of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  17. Review
  18. Review
  19. NANOBODIES®: A Review of Diagnostic and Therapeutic ApplicationsInternational journal of molecular sciences · 2023
    Review
  20. PET/MR imaging of inflammation in atherosclerosis.Nature biomedical engineering · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Max L SendersTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Medical Biochemistry, Academic Medical Center, Amsterdam, the Netherlands.
Sophie HernotIn Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.
Giuseppe CarlucciBernard and Irene Schwarz Center for Biomedical Imaging, New York University, New York, New York; Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Jan C van de VoortTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Francois FayTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Chemistry, York College of The City University of New York, New York, New York.
Claudia CalcagnoTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Jun TangDepartment of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Amr AlaargTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Biomaterials Science and Technology, Technical Medical Centre. University of Twente, Enschede, the Netherlands.
Yiming ZhaoTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Seigo IshinoTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Anna PalmisanoTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Unit of Clinical Research in Radiology, Experimental Imaging Center, San Raffaele Scientific Institute, Milan, Italy.
Gilles BoeykensTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Anu E MeerwaldtTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Brenda L Sanchez-GaytanTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Samantha BaxterTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Laura ZendmanTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Mark E LobattoDepartment of Radiology, Academic Medical Center, Amsterdam, the Netherlands.
Nicolas A KarakatsanisTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Philip M RobsonTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Alexis BroisatBioclinic Radiopharmaceutics Laboratory, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche S 1039, Grenoble, France.
Geert RaesResearch Group of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium; Laboratory of Myeloid Cell Immunology, Vlaams Instituut voor Biotechnologie Inflammation Research Center, Ghent, Belgium.
Jason S LewisDepartment of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Radiology, Weill Cornell Medical College, New York, New York; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Sotirios TsimikasDivision of Cardiovascular Diseases, Sulpizio Cardiovascular Center, Department of Medicine, University of California-La Jolla, San Diego, California.
Thomas ReinerDepartment of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Radiology, Weill Cornell Medical College, New York, New York.
Zahi A FayadTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Nick DevoogdtIn Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.
Willem J M MulderTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Medical Biochemistry, Academic Medical Center, Amsterdam, the Netherlands. Electronic address: willem.mulder@mssm.edu.
Carlos Pérez-MedinaTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: carlos.perez-medina@mountsinai.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Translational imaging and nanomedicine in inflammatory atherosclerosisP01HL131478 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Zahi A. Fayad · 2017 to 2026
$24.3M
TR&D 4: Revealing Microstructure: Biophysical modeling and validation for discovery and clinical careP41EB017183 · NIBIB · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Hersh Chandarana · 2014 to 2026
$19.3M
MR/PET Imaging of coronary atherosclerosisR01HL071021 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FAYAD, ZAHI A. · 2002 to 2019
$7.8M
Theranostic HDL nanoparticles for inflammatory macrophages in atherosclerosisR01EB009638 · NIBIB · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FAYAD, ZAHI A. · 2009 to 2016
$4.6M
PET/MRI to study nanotherapy in atherosclerosisR01HL125703 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, WILLEM · 2015 to 2018
$2.4M
Anti-inflammatory nanoparticle formulations to treat atherosclerosisR01HL118440 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, WILLEM, NAHRENDORF, MATTHIAS · 2014 to 2017
$2.3M
NCI NIH HHS P30 CA008748NHLBI NIH HHS P01 HL131478NHLBI NIH HHS R01 HL071021NHLBI NIH HHS R01 HL118440NHLBI NIH HHS R01 HL125703NIBIB NIH HHS P41 EB017183NIBIB NIH HHS R01 EB009638
6 · The paper itself

Abstract

objectivesThis study sought to develop an integrative positron emission tomography (PET) with magnetic resonance imaging (MRI) procedure for accurate atherosclerotic plaque phenotyping, facilitated by clinically approved and nanobody radiotracers.

backgroundNoninvasive characterization of atherosclerosis remains a challenge in clinical practice. The limitations of current diagnostic methods demonstrate that, in addition to atherosclerotic plaque morphology and composition, disease activity needs to be evaluated.

methodsWe screened 3 nanobody radiotracers targeted to different biomarkers of atherosclerosis progression, namely vascular cell adhesion molecule (VCAM)-1, lectin-like oxidized low-density lipoprotein receptor (LOX)-1, and macrophage mannose receptor (MMR). The nanobodies, initially radiolabeled with copper-64 (

resultsThe 3 nanobody radiotracers accumulated in atherosclerotic plaques and displayed short circulation times due to fast renal clearance. The MMR nanobody was selected for labeling with gallium-68 (

conclusionsWe have evaluated nanobody-based radiotracers in rabbits and developed an integrative PET/MRI protocol that allows noninvasive assessment of different processes relevant to atherosclerosis progression. This approach allows the multiparametric study of atherosclerosis and can aid in early stage anti-atherosclerosis drug trials.

Indexed as

Multiparametric Magnetic Resonance ImagingPlaque, AtheroscleroticPositron-Emission TomographyAnimalsAtherosclerosisDisease Models, AnimalDisease ProgressionEarly DiagnosisGenetic Predisposition to DiseaseLectins, C-TypeMannose-Binding LectinsMannose ReceptorMice, Knockout, ApoEMultimodal ImagingPhenotypeRabbitsLectins, C-TypeMannose-Binding LectinsMannose ReceptorOlr1 protein, mouseRadiopharmaceuticalsReceptors, Cell SurfaceScavenger Receptors, Class ESingle-Domain AntibodiesVascular Cell Adhesion Molecule-1atherosclerosismolecular imagingnanobodyPET/MRI

Identifiers

PMID30343086
PMCPMC6461528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.